Logo of Recce Pharmaceuticals (ASX:RCE)Latest Recce Pharmaceuticals (ASX:RCE) News

Page 3
Page 3 of 5

Healthcare Wrap - Week 17 (20 Apr -> 24 Apr) 2026

Healthcare stocks delivered a mix of capital raisings, product approvals and trial wins, but many early share price jumps did not last. The biggest moves came from Patrys, Firebrick Pharma and 4DMedical, where investors reacted fast to funding news and then kept testing how much near-term value was really on offer.
Logan Eniac
25 Apr 2026

Recce Pharmaceuticals Passes Key Indonesian Inspection for Phase 3 Diabetic Foot Infection Trial

Recce Pharmaceuticals has cleared a critical regulatory hurdle in Indonesia with a successful inspection of its Phase 3 clinical trial site for diabetic foot infections, paving the way for potential approval in 2026 amid a large and growing market.
Ada Torres
21 Apr 2026

Healthcare Wrap - Week 13 (23 Mar -> 27 Mar) 2026

Cancer drug data and two separate Mayo Clinic-linked deals drove the biggest moves this week. Investors paid up for clearer routes to hospital rollouts, while one digital screening name fell hard after early gains evaporated.
Logan Eniac
28 Mar 2026

Recce Pharmaceuticals Secures Key Patent in Brazil’s Growing Antibiotics Market

Recce Pharmaceuticals has expanded its intellectual property footprint with a newly granted patent in Brazil, protecting its innovative synthetic anti-infectives against a broad range of infections. This milestone strengthens Recce’s position in one of South America’s largest antibiotic markets.
Ada Torres
24 Mar 2026

Market Wrap - Week 12 (16 Mar -> 20 Mar) 2026

A brutal split opened up in small caps: a few stocks surged on hard approvals and funding, while many resource names slid even after announcing big numbers. The week’s tape looked simple: investors paid for certainty and sold anything that still needs time, permits, or more cash.
Logan Eniac
21 Mar 2026

Healthcare Wrap - Week 12 (16 Mar -> 20 Mar) 2026

A handful of small caps did the heavy lifting this week, led by a lung cancer trial green light and a steep sell-off after a capital raise. Investors paid up for clear clinical steps, but punished dilution and stocks that reopened lower and kept sliding.
Logan Eniac
21 Mar 2026

Recce Pharmaceuticals Advances Synthetic Antibiotic RECCE 327 with ASEAN Registration Targeted for 2026

Recce Pharmaceuticals is progressing its Phase 3 clinical trial of RECCE 327, a novel synthetic antibiotic targeting multidrug-resistant infections, with interim data from Indonesia supporting registration plans across ASEAN by 2026.
Ada Torres
19 Mar 2026

Healthcare Wrap - Week 9 (23 Feb -> 27 Feb) 2026

Cannabis and psychedelics delivered the week’s biggest winner, while a cluster of smaller caps slid on fresh losses, leadership change, and near-term uncertainty. Investors kept paying up for FDA clearances and reimbursement wins, but punished businesses where early pops quickly disappeared.
Logan Eniac
28 Feb 2026

Recce Pharmaceuticals’ Loss Widens as Clinical Trials Advance and Funding Secured

Recce Pharmaceuticals reported a doubling of its net loss for the half-year ended December 2025 amid significant progress in its anti-infective drug development and a substantial funding boost. The company is advancing Phase 3 trials and expanding its patent portfolio while managing financial pressures.
Ada Torres
27 Feb 2026

Healthcare Wrap - Week 6 (2 Feb -> 6 Feb) 2026

A single diagnostics update sparked a breakout week, while a handful of biotech names sold off hard despite busy newsflow. Capital raisings, takeover steps and US market pushes kept healthcare in motion heading into mid-February milestones.
Logan Eniac
7 Feb 2026

Recce Pharmaceuticals Deepens U.S. Army Ties to Combat Burn Wound Infections

Recce Pharmaceuticals has secured a second Cooperative Research and Development Agreement with the U.S. Army Institute of Surgical Research to test its RECCE 327 Gel in burn wound infection models, underscoring growing military interest in its synthetic anti-infectives.
Ada Torres
2 Feb 2026

Healthcare Wrap - Week 5 (26 Jan -> 30 Jan) 2026

A handful of healthcare names did the heavy lifting this week, driven by FDA wins, guideline upgrades, and big shifts in sales and cashflow. The flip side: several clinical-stage stocks fell hard as investors stayed picky about near-term proof and funding.
Logan Eniac
31 Jan 2026